Patent ID: 6350784
Filing Date: 2002-02-26
Classification: A61K,A61P,C07D

Abstract:
A method for use in treating human immunedeficiency virus, comprising the steps of:systemically applying an antimicrobial compound with a syringe into a rectal canal or vagina of a person infected with human immunedeficiency virus; said antimicrobial compound comprises by weight: from about 40% to about 60% of a phytochemical concentrate of herbaceous botanicals consisting of Commiphora myrrha and Echinacea purpurea; said phytochemical concentrate of Commiphora myrhha and Echinacea purpurea providing antimicrobial isolates; from about 20% to about 60% sterile water providing a diluent and carrier for said phytochemical concentrate; from about 0.02% to about 0.30% ammonium salt surfactant comprising benzalkonium chloride; from about 2% to about 12% folic acid providing a nutrient; and said folic acid cooperating with said Commiphora myrrha and said Echinacea purpurea to treat human immunedeficiency virus; applying said antimicrobial compound in sufficient concentration and a sufficient period of time to decrease human immunedeficiency virus in the patient; controlling viral load; and said antimicrobial isolates of said phytochemical concentrate, comprises by weight based upon the total weight of the medical composition: from about 0.3% to about 9% echinacoside; from about 0.1% to about 7% PSI (4-O-methylglucoronoarabinoxylan, Mr 35 kD) and PSI (acid rhamnoarabinogalactan, Mr 450 kD); from about 0.1% to about 10% cynarin (1,5-di-o-caffeoylquinic acid) and chioric acid (2,3-O-di-caffeoyltartaric acid) and derivatives thereof; from about 0.2% to about 4% echinolone; from about 0.2% to about 8% echinacin B; from about 0.1 to about 6% echinaceine; from about 2% to about 7% anthonocyanins comprising cynanidin 3-O-B-D-glucopyranoside and 3-O-(6-O-malonyl)-B-D-glucopyranoside; from about 0.01% to about 0.06% pyrrolizidine alkaloids comprising tussilagine and isotussilagine; from about 0.003% to about 0.009% isomeric dodeca isobutyalamides and tetroenoic acid; and Commophora myrrha phytochemicals comprising members selected from the group consisting of: caryophylenes, sequiterpenes, curzerenone, dihydro fuanodien-6-one; 2-methoxyfuradine, elemol, lyndesterene, acetic acid, alpha-amyrone, arabinose, alpha-bisabolene, gamma-bisabolene, cadinene, campesterol, cholesterol, cinnamaldehyde, commiferin, alpha-commiphoric acid, beta-commiphoric acid, gama-commiphoric acid, commiphorinic acid, m-cresol, cumic alcohol, cuminaldehyde, dipentene, elemol, 3-epi-alpha-amyrin, eugenol, furanodiene, furanodienone, galactose, gum, heerabolene, alpha-heerabomyrrhol, beta-heerabomyrrhol, heeraboresene, limonene, 4-O-methyl-glucuronic acid, n-nonacesane, beta-sitosterol, xylose.